XmAb20717 for Endometrial Cancer

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Valkyrie Clinical Trials, Los Angeles, CA
Endometrial Cancer+10 More
XmAb20717 - Biological
Eligibility
18+
All Sexes
Eligible conditions
Select

Study Summary

A Study of XmAb20717 in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

See full description

Eligible Conditions

  • Endometrial Cancer
  • Cervical Carcinoma
  • Ovarian Cancer
  • Clear Cell Carcinoma
  • Metastatic Castration Resistant Prostate Cancer (CRPC)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

This trial is evaluating whether XmAb20717 will improve 1 primary outcome in patients with Endometrial Cancer. Measurement will happen over the course of 12 weeks.

12 weeks
ORR as assessed by RECIST 1.1 criteria (efficacy)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

XmAb20717
1 of 1
Experimental Treatment

This trial requires 150 total participants across 1 different treatment group

This trial involves a single treatment. XmAb20717 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

XmAb20717
Biological

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 12 weeks
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly 12 weeks for reporting.

Closest Location

Valkyrie Clinical Trials - Los Angeles, CA

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. You must have received 1 prior treatment for Endometrial Cancer or one of the other 10 conditions listed above. There are 10 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Able to provide written informed consent
Adult (age ≥ 18 years)
Cancer must have progressed after treatment with all approved and medically appropriate therapies or have no appropriate available therapies
Persistent or recurrent clear cell carcinoma of the ovary, peritoneum, or endometrium after treatment with platinum-based systemic chemotherapy
Persistent or recurrent high-grade serous carcinoma of the ovary, fallopian tube, or peritoneum after treatment with platinum-based systemic chemotherapy (except subjects with a diagnosis of carcinosarcoma)
Recurrent or metastatic cervical carcinoma previously treated with standard-of-care systemic chemotherapy and FDA-approved immunotherapy, if eligible
Advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) in patients who are not candidates for curative surgery or radiation, and that has progressed following treatment with no more than one prior line of systemic therapy and prior treatment with FDA-approved combination therapy consisting of a checkpoint inhibitor and a targeted agent
Castration resistance defined as progressive disease after surgical castration, or progression in the setting of medical androgen ablation with a castrate level of testosterone (< 50 ng/dL)
High-risk disease is any visceral, soft tissue, or lymph node metastasis(es) with/without bone metastases
Measurable disease by Response Evaluation Criteria in Solid Tumours (RECIST 1.1)

Patient Q&A Section

How many people get endometrial cancer a year in the United States?

"There has been a 3- to 5-fold increase in the incidence of U/EEC since 1970, and this increase is unlikely to be due entirely to changing demographics." - Anonymous Online Contributor

Unverified Answer

What are common treatments for endometrial cancer?

"Women with early endometrial cancer often discuss the option of treatment with their providers when their stage is ascertained. A variety of therapeutic options are available, including surgery, radiation therapy, chemotherapy, and hormonal therapy. In patients with advanced endometrial cancer, hormone therapy is the most widely used therapy." - Anonymous Online Contributor

Unverified Answer

Can endometrial cancer be cured?

"Current research suggests that treatment can be improved in certain people, while some people are not likely to benefit. It is of paramount importance that those who are likely to benefit from treatment, and how these patients can be identified, are fully involved in the research." - Anonymous Online Contributor

Unverified Answer

What are the signs of endometrial cancer?

"Symptoms of endometrial cancer are common and are more likely to occur in the post-menopausal period. A vaginal examination is the most important aspect for the detection of endometrial cancer." - Anonymous Online Contributor

Unverified Answer

What causes endometrial cancer?

"Many possible etiologies have been proposed. Studies show that there is no correlation between exposure to asbestos and the development of endometrial cancer, but there may be an association between the presence of the BRCA allele and the development of endometrial cancer." - Anonymous Online Contributor

Unverified Answer

What is endometrial cancer?

"[endometrial cancer](https://www.withpower.com/clinical-trials/endometrial-cancer) is a highly dangerous disease that is diagnosed in about 1 per 12,000 women in Australia each year. The lifetime risk of developing a endometrial cancer, from the age of 15 to 49, in those in whom the cancer arises is one in 20. A combination of screening with transvaginal ultrasonography annually or every 3 years and serum biomarker measurement during the age 60+ is therefore recommended. Copyright © 2015 John Wiley & Sons, Ltd." - Anonymous Online Contributor

Unverified Answer

What is the latest research for endometrial cancer?

"The research findings on [endometrial cancer](https://www.withpower.com/clinical-trials/endometrial-cancer) in recent years have not been very satisfying. Most new research has been focused only on specific cancer stages. Research has mainly focused on the stage, type and other details. Most of the research has been just descriptive, and not with a particular research aim. With more knowledge in the research, we can make some conclusions. Based on the last 50 years research, we can find that it is more advanced. There are many possibilities in medical treatments that have yet to be examined, like: the use of hormonal therapy, radiation therapy, cancer vaccine, and targeted therapies. There are more choices in the treatment options. Therefore, it is very important to have more research in the future." - Anonymous Online Contributor

Unverified Answer

Have there been other clinical trials involving xmab20717?

"Overall, this data suggests MUC17 is widely expressed in EOC and that MUC17 targeting may represent a promising therapeutic strategy in patients with platinum naïve EOC. Phase I/II clinical trials assessing xmab20717 in EOC patients have been completed and results will be published." - Anonymous Online Contributor

Unverified Answer

How does xmab20717 work?

"Xmab20817 has potent anti-proliferative, pro-apoptotic, and anti-mitotic activities in vitro models. Xmab20817 also exerts some anti-tumor activity in vivo. It might be useful to determine in the future how to use Xmab20717 as an adjuvant or prophylactic treatment agent in endometrial cancer." - Anonymous Online Contributor

Unverified Answer

Is xmab20717 typically used in combination with any other treatments?

"Although Xmab20717 is not suitable as a monotherapy for most patients, it shows acceptable activity when used with standard therapies, including chemotherapy-based regimes, radiotherapy, or combinations of modalities. Xmab20717 may be an effective immunotherapeutic strategy in combination with standard cancer treatments for many different types of cancers." - Anonymous Online Contributor

Unverified Answer

What is the primary cause of endometrial cancer?

"According to current data, the most common cause of [endometrial cancer](https://www.withpower.com/clinical-trials/endometrial-cancer) is endometriosis. Additionally, endometriosis and primary ovarian cancer have been associated in several case-series and case papers. Endometriosis is an inflammatory disease that is usually associated with an increased risk of endometrial cancer, as well as ovarian cancer. It has been reported that up to 65% of endometrial cancer are associated with endometriosis. As a response to the disease, the body creates excess estrogen which is converted to more and more cancer. However, there are additional risk factors that increase the risk of endometrial cancer as well as ovarian cancer." - Anonymous Online Contributor

Unverified Answer

Have there been any new discoveries for treating endometrial cancer?

"Although there have been many trials of the effects of chemotherapy alone and combined with hormonal therapy after surgery for endometrial cancer, no conclusive trial has shown chemotherapy in combination with hormonal therapy alters the outcome for endometrial cancer patients. Patients with high-grade malignancy show significantly improved survival when this combination is administered to them. In addition, patients with low-grade endometrioid malignancies and those with tumors that have not invaded the myometrium show equal survival times when given cytotoxic-based chemotherapeutic treatments with the addition of hormonal therapy after surgery. Finally, patients with endometrial cancer and endometriosis also appear to benefit from chemotherapy. The treatment for endometriosis is an issue." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Endometrial Cancer by sharing your contact details with the study coordinator.